Pre-made Atinumab biosimilar ( Whole mAb, anti-RTN4 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-037
Anti-RTN4 therapeutic antibody (Pre-made Atinumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
ATI 355, a monoclonal antibody product targeting the Nogo-A protein, is being developed by Novartis for the treatment of spinal cord injuries. Clinical.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-RTN4 therapeutic antibody (Pre-made Atinumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Spinal cord injuries|